ChromoCure, Inc., a developer and provider of proprietary cancer detection systems, recently announced a co-development agreement with the company’s primary cell preparation and application technology supplier. Under the terms of the agreement, ChromoCure will co-develop a fully integrated chromosomal scanner system for nationwide distribution to pathology and related cancer detection labs.

ChromoCure will collaborate with companies and joint technical research and development efforts to complete a fully automated hybridization system allowing for a complete chromosomal scanning solution. The CS300 system has the ability to perform a full 23-pair chromosomal cross-sectioning for every cell within a sample, while integrating solid tumor incubation equipment for therapeutic and cancer cure protocols testing.

As a leading provider of non-toxic and non-invasive approaches to cancer therapy and cure research, ChromoCure’s systems measure the unique genomic characteristic found in 100 percent of all cancers and never found in normal cells. The company believes its technology is superior and will become the gold standard for cancer detection worldwide.